Stem Cells Archives | Page 100 of 202

5 Questions to Ask Your Doctor About Stem Cell Transplants

June 21, 2020 By Cade Hildreth, Founder & President Leave a Comment

Stem cell transplants are used to treat certain types of cancer as well as some other conditions. Stem cell transplants have even completely eradicated HIV in some patients.

If you are considering stem cell transplants for your health issues, you will understandably have a lot of questions.

Knowing the right questions to ask about this complex procedure isn’t always that easy, however. We’re here to help with that.

Read on as we look at five important questions to ask your doctor about stem cell transplants. [Read more…]

Cynata to Launch World’s First Phase 3 Trial with an iPSC-Derived Cell Therapeutic

June 18, 2020 By Cade Hildreth, Founder & President Leave a Comment

With an anticipated enrollment of 440 patients, it will be the world’s largest trial ever completed with an iPSC-derived cell therapeutic.

It’s official. Australian stem cell company Cynata Therapeutics is preparing to test its iPSC-derived cell therapeutic, CYP 004, in a Phase 3 clinical trial enrolling up to 440 patients. Led by the University of Sydney and funded by the Australian Government National Health and Medical Research Council (NHMRC), the historic trial will assess whether Cynata’s cell therapeutic, CYP-004, has the capacity to improve patient outcomes in osteoarthritis (OA).

CYP-004 is an allogeneic, iPSC-derived mesenchymal stem cell (MSC) product derived using Cynata’s proprietary Cymerus™ technology. The clinical trial is set to achieve two world-firsts:

It will be the world’s first clinical trial involving an iPSC-derived cell therapeutic product to enter Phase 3.
It will be the largest trial ever completed with an iPSC-derived cell therapeutic, with an anticipated enrollment of 440 patients.

[Read more…]

Gamida Cell, President Dr. Yael Margolin Reveals the Unmet Need in HSCT

June 1, 2020 By Cade Hildreth, Founder & President Leave a Comment

Dr. Yael Margolin, CEO of Gamida Cell — Dr. Yael Margolin, President of Gamida Cell

Gamida Cell is a cell therapy company that is best known for its innovative approaches to hematopoietic stem cell transplantation (HSCT). Headquartered in Jerusalem, Israel, Gamida Cell has been advancing several clinical programs using ex vivo expanded hematopoietic stem cells (HSCs) created using its proprietary nicotinamide (NAM) technology.

I had the honor of interviewing Dr. Yael Margolin, President of Gamida Cell. In this interview, we discuss how Gamida Cell is using cell therapeutics to address the unmet need in hematopoietic stem cell transplantation (HSCT). [Read more…]

Fate Therapeutics’ CRISPR-edited, iPSC-derived Cell Therapy Cleared for Clinical Investigation

May 29, 2020 By Cade Hildreth, Founder & President Leave a Comment

Fate Therapeutics Announces FDA Clearance of IND Application for FT538, First CRISPR-edited, iPSC-derived Cell Therapy

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for cancer and immune disorders, announced the U.S. FDA has cleared its Investigational New Drug (IND) application for FT538.

FT538 is the first CRISPR-edited, iPSC-derived cell therapy under development worldwide. [Read more…]

Generation of iPSC-derived Parkinson’s Disease Neurons

May 28, 2020 By Cade Hildreth, Founder & President 6 Comments

Author: Jean-Philippe Richard, Ph. D. ([email protected])

Parkinson’s Disease (PD) affects some 10 million people worldwide, most commonly in patients over the age of 50. PD is associated with the loss of dopaminergic neurons in the substantia nigra region of the brain, leading to the characteristic tremors in the extremities, among other symptoms. There is a need for models of PD to help discover new therapies. To help address this need, we generated and characterized iPSC-derived PD dopaminergic neurons as a test case for functional neural differentiation. [Read more…]